Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

The iPhone maker's shares [rallied for a second day]( ...

Eli Lilly is investing money to help a smaller biotech develop a new class of small-molecule drugs. This move is another in a ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

(Reuters) -European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...